Nugent, Allison C.
Ballard, Elizabeth D.
Gould, Todd D.
Park, Lawrence T. http://orcid.org/0000-0002-6570-686X
Moaddel, Ruin
Brutsche, Nancy E.
Zarate, Carlos A. Jr.
Article History
Received: 13 July 2017
Revised: 13 July 2017
Accepted: 3 November 2017
First Online: 27 February 2018
Compliance with ethical standards
:
: Funding for this work was supported by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; NCT00088699/04-M-0222/ZIA MH002857), by a NARSAD Independent Investigator Award to C.A.Z., and by a Brain and Behavior Mood Disorders Research Award to C.A.Z. C.A.Z. is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. C.A.Z. is listed as a co-inventor on a patent for the use of (2 <i>R</i>,6 <i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain. C.A.Z. is listed as co-inventor on a patent application for the use of (2 <i>R</i>,6 <i>R</i>)-hydroxynorketamine and (2 <i>S</i>,6 <i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and PTSDs; he has assigned his patent rights to the US government, but will share a percentage of any royalties that may be received by the government. The remaining authors declare that they have no conflict of interest.